Preventives or remedies for atopic dermatitis

• US 20030185864A1
• Filed: 01/17/2003
• Published: 10/02/2003
• Est. Priority Date: 07/19/2000
• Status: Abandoned Application

• Current Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited)
• Original Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited)
• Inventors: Takekoshi, Yoichiro, Takahashi, Tomoya, Kobayashi, Asako
• Application Number:
  US10/333,322
• Publication Number:
  US 20030185864A1
• Time in Patent Office: Days
• US Class Current: 424/401
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 8/02 characterised by special physical form
• CPC Class Codes: A61K 8/0208 Tissues; Wipes; Patches
• CPC Class Codes: A61K 8/0212 Face masks
• CPC Class Codes: A61K 8/492 having condensed rings, e.g. indol
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 17/00 Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin

Abstract

The present invention provides skin epidermal ceramide synthesis accelerators, agents for improving skin epidermal barrier function and agents for preventing or improving atopic dermatitis, which each comprises, as an active ingredient, hydroxyproline or an N-acyl derivative of hydroxyproline, or a salt thereof, and cosmetics for improving skin barrier function or improving atopic dermatitis, which comprises the ceramide synthesis accelerator.

Claims

1. A skin epidermal ceramide synthesis accelerator which comprises, as an active ingredient, hydroxyproline or an N-acyl derivative of hydroxyproline, or a salt thereof.

2. The skin epidermal ceramide synthesis accelerator according to claim 1, wherein the hydroxyproline or the N-acyl derivative of hydroxyproline, or the salt thereof is contained in an amount of 0.01 to 20% by weight based on the total weight.

3. The skin epidermal ceramide synthesis accelerator according to claim 1 or 2, wherein the N-acyl derivative of hydroxyproline is an N-acetylated derivative, an N-propionylated derivative, an N-butyrylated derivative or an isobutyrylated derivative of hydroxyproline.

4. The skin epidermal ceramide synthesis accelerator according to any one of claims 1 to 3, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is an N-acyl derivative of hydroxyproline selected from the group consisting of cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.

5. The skin epidermal ceramide synthesis accelerator according to any one of claims 1 to 4, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is hydroxyproline produced by a microorganism.

6. The skin epidermal ceramide synthesis accelerator according to claim 5, wherein the microorganism is a microorganism into which a proline 3-hydroxylase gene or a proline 4-hydroxylase gene derived from a microorganism belonging to a genus selected from the genus Amycolatopsis, the genus Dactylosporangium and the genus Streptomyces is introduced.

19. A cosmetic for improving skin barrier function or improving atopic dermatitis, which comprises the ceramide synthesis accelerator according to any one of claims 1 to 6.

7. An agent for improving skin epidermal barrier function which comprises, as an active ingredient, hydroxyproline or an N-acyl derivative of hydroxyproline, or a salt thereof.

8. The agent for improving skin epidermal barrier function according to claim 7, wherein the hydroxyproline or the N-acyl derivative of hydroxyproline, or the salt thereof is contained in an amount of 0.01 to 20% by weight based on the total weight.

9. The agent for improving skin epidermal barrier function according to claim 7 or 8, wherein the N-acyl derivative of hydroxyproline is an N-acetylated derivative, an N-propionylated derivative, an N-butyrylated derivative or an isobutyrylated derivative of hydroxyproline.

10. The agent for improving skin epidermal,barrier function according to any one of claims 7 to 9, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is an N-acyl derivative of hydroxyproline selected from the group consisting of cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.

11. The agent for improving skin epidermal barrier function according to any one of claims 7 to 10, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is hydroxyproline produced by a microorganism.

12. The agent for improving skin epidermal barrier function according to claim 11, wherein the microorganism is a microorganism into which a proline 3-hydroxylase gene or a proline 4-hydroxylase gene derived from a microorganism belonging to a genus selected from the genus Amycolatopsis, the genus Dactylosporangium and the genus Streptomyces is introduced.

13. An agent for preventing or improving atopic dermatitis which comprises, as an active ingredient, hydroxyproline or an N-acyl derivative of hydroxyproline, or a salt thereof.

14. The agent for preventing or improving atopic dermatitis according to claim 13, wherein the hydroxyproline or the N-acyl derivative of hydroxyproline, or the salt thereof is contained in an amount of 0.01 to 20% by weight based on the total weight.

15. The agent for preventing or improving atopic dermatitis according to claim 13 or 14, wherein the N-acyl derivative of hydroxyproline is an N-acetylated derivative, an N-propionylated derivative, an N-butyrylated derivative or an isobutyrylated derivative of hydroxyproline.

16. The agent for preventing or improving atopic dermatitis according to any one of claims 13 to 15, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is an N-acyl derivative of hydroxyproline selected from the group consisting of cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.

17. The agent for preventing or improving atopic dermatitis according to any one of claims 13 to 16, wherein the hydroxyproline or hydroxyproline in the N-acyl derivative of hydroxyproline is hydroxyproline produced by a microorganism.

18. The agent for preventing or improving atopic dermatitis according to claim 17, wherein the microorganism is a microorganism into which a proline 3-hydroxylase gene or a proline 4-hydroxylase gene derived from a microorganism belonging to a genus selected from the genus Amycolatopsis, the genus Dactylosporangium and the genus Streptomyces is introduced.